13F Holdings
中文EN

ALGS Aligos Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1799448 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY122.2%
TTM net income YoY23.3%
TTM EPS YoY52.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,244.2%
Net margin-1,137.2%
FCF margin—
EBITDA margin-1,223.5%

Returns

ROE-159.5%
ROA-84.5%
ROIC (approx.)-1,147.1%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets76.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio2.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.19M$3.61M$6.19M$0$0
R&D expense$69.45M$70.27M$73.04M$85.08M$104.15M
SG&A expense$20.72M$22.83M$30.62M$26.41M$28.53M
Operating income-$87.98M-$89.15M-$88.13M-$97.58M-$128.32M
Pretax income-$23.88M-$130.88M-$86.88M-$95.94M-$128.19M
Income tax$314,000$331,000$795,000$106,000$143,000
Net income-$24.19M-$131.21M-$87.68M-$96.05M-$128.33M
EBITDA-$87.06M-$88.13M-$86.57M-$95.27M-$125.30M
EPS (basic)-2.45-20.94-34.20-2.25-3.22
EPS (diluted)-2.45-20.94-34.20-2.25-3.22
Weighted avg. shares (diluted)9.88M6.26M2.56M42.70M39.86M
Banking
Net interest income$2.20M$1.70M$4.30M$1.50M—
Balance sheet
Cash & equivalents$18.30M$37.11M$135.77M$81.46M$186.98M
Short-term investments$59.54M$19.94M—$44.48M$3.92M
Current assets$82.86M$62.14M$141.08M$133.54M$204.42M
PP&E, net$1.87M$2.36M$3.26M$4.82M$6.18M
Total assets$88.53M$70.09M$151.53M$146.69M$235.37M
Current liabilities$21.23M$21.74M$23.91M$33.13M$38.96M
Total liabilities$34.99M$99.07M$59.45M$42.79M$50.64M
Shareholders' equity$53.55M-$28.97M$92.08M$103.90M$184.73M
Shares outstanding6.18M3.86M3.00M42.92M42.69M
Cash flow statement
Operating cash flow-$82.50M-$80.74M-$79.00M-$79.39M-$115.66M
Capital expenditure—$130,000$19,000$943,000$892,000
Free cash flow—-$80.87M-$79.02M-$80.33M-$116.55M
Investing cash flow-$37.83M-$18.28M$44.98M-$26.29M$3.02M
Financing cash flow$101.64M$355,000$88.33M$164,000$78.68M
Depreciation & amortization$930,000$1.03M$1.56M$2.31M$3.02M
Stock-based compensation$5.04M$8.45M$12.65M$14.69M$13.46M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.